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S250 Poster Session IStandard of care HCT requires the patient with SCD to be less
than 16 years of age and have an HLA-matched, SCD-free sibling.
However, only about 14% of children with SCD have such a sibling.
In-vitro fertilization combined with pre-implantation genetic diag-
nosis, known as in-vitro fertilization with therapeutic intent
(IVFTI), makes it possible for parents to select a compatible, unaf-
fected embryo to implant and carry to term.
European investigators have published the birth of matched,
SCD-free sibling donors via IVFTI, but in the United States it re-
mains unreported in the medical literature and appears underutil-
ized, begging the question of why this combination of therapeutic
procedures has not been more widely offered, performed, or re-
ported in the U.S. pediatric SCD community.
We interviewed 22 adult SCD patients and parents/caregivers of
pediatric SCD patients to better understand their attitudes toward
IVFTI and HCT, and the barriers that prevent use of these thera-
peutic procedures.
Most interviewees (20 of 22 subjects) believed that the benefits of
matched-sibling HCT to the child outweighed the risks.
Most interviewees (15) were unaware SCD could be cured by
HCT.
After learning about IVFTI, 14 interviewees were interested in
pursuing it. The vast majority of interviewees (19) believed that
IVFTI should be offered to all SCD families before their affected
child becomes HCT ineligible due to age.
Every interviewee (22) claimed that the cost of IVFTIwas a barrier
to access and that insurance coverage would increase IVFTI use.
Currently, IVFTI is not covered by a large number of insurance pro-
viders, including Medicaid.
Lack of information and high costs are twomajor barriers prevent-
ing children with SCD from benefiting from IVFTI.
Pediatric SCD patients’ lack of access to IVFTI and, therefore,
matched-sibling HCT demonstrates the extent to which healthcare
disparities plague the SCD community. As SCDprimarily affects Af-
rican-American and Latino children, most of whom subscribe to
Medicaid, the lack of awareness and underutilization of this available
combination of therapies is not only an issue of clinical importance,
but also one of social justice.247
HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTATION IN 36 PEDIATRIC PATIENTS WITH SEVERE ACQUIRED
APLASTIC ANAEMIA
Ghavamzadeh, A., Hamidieh, A.A., Jahani, M., Alimoghaddam, K.,
Iravani, M., Mousavi, S.A., Bahar, B., Khodabandeh, A., Jalili, M. Teh-
ran University of Medical Sciences, Tehran, Islamic Republic of Iran
Objective: Severe acquired aplastic anemia (SAA) is a rare disease of
childhood. Matched related hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for pediatric patients with SAA.
Immunosuppressive therapy is the alternative treatment in children
with SAA who do not have a donor. We retrospectively analyzed pe-
diatric patients who received allogeneic HSCT from HLA-matched
related donors at our institution.
Methods: Between March 1993 and October 2009, 36 patients (12
female, 24 male) below 15 years old with multitransfused SAA re-
ceived allogeneic HSCT fromHLA-matched related donors (33 sib-
lings and 3 other relatives). Median age was 11 years (range 1 to 15
years). The graft source was bone marrow in 22 patients, peripheral
blood stem cells in 13 patients and 1 patient received both bonemar-
row and peripheral blood. All patients were conditioned with a mye-
loablative regimen containing cyclophosphamide, and
antithymocyte globulin. For graft-versus-host disease (GVHD) pro-
phylaxis, we used cyclosporine and methotrexate at the standard
doses.
Results: With a median follow-up of 30 months (range, 1-106
months), overall survival was 94% and was not statistically signif-
icant different between the patients receiving bone marrow trans-
plants and those receiving peripheral blood transplants. The
median time to neutrophil engraftment (absolute neutrophil
count .0.510^9/L) was +13 and median time to platelet en-
graftment (platelet count .2010^9/L) was +19. Grade III–IV
acute GVHD occurred in 7(19.4%) patients. The cumulative in-cidence of chronic GVHD for those who survived more than 100
days was 8.3%. 2-year disease-free survival was 83.3% and 2-year
overall-free survival was 94%. At present 30 of 36 patients are
alive with normal hematologic parameters and full donor chime-
rism and doing well. The number of patients who not engrafted
was 4 (11.7%) and mortality rate was 2(5.5%).The causes of
death included infection in both of patients.
Conclusions:These results confirm previous studies that condition-
ing with amyeloablative regimen allows for sustained engraftment of
HLA-matched related donor grafts in most multitransfused SAA pe-
diatric patients and is associated with low incidences of GVHD, low
toxicity, and long-term survival.248
THE USE OF DAY 100 PLATELET COUNT TO IDENTIFY PEDIATRIC ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AT IN-
CREASED RISK OF MORTALITY
Sussman, L.1, Duncan, C.N.2,3, Whitley, K.2,3, Lehmann, L.E.2,3 1 Skid-
more College, Saratoga Springs, NY; 2 Children’s Hospital, Boston, MA;
3 Dana Farber Cancer Institute, Boston, MA
Background: Scoring systems based on pre-hematopoietic stem
cell transplant (HSCT) evaluation and co-existing morbidities
have been validated and used to assign risk of adverse outcome,
particularly for adult patients. Currently, there is no standard
method of re-assessing risk for those who have survived the acute
transplant period. Despite advances in supportive care, patients
remain vulnerable to death from both relapse and transplant-re-
lated mortality (TRM) beyond the 100 day mark. Platelet counts
are easily obtainable and routinely checked at post-HSCT visits.
We analyzed the platelet count 100 days post transplant to deter-
mine if values \100,000 are associated with increased mortality
in pediatric allogeneic HSCT patients.
Methods: Retrospective data on 161 consecutive patients undergo-
ing allogeneic HCST at Children’s Hospital Boston/Dana Farber
from 1/1/05– 8/1/08 were reviewed; we report on 143 of the151 pa-
tients alive at D100. Patient age/gender, diagnosis, donor, condi-
tioning and post-transplant complications (GVHD, relapse and
death) were collected. Patients ranged in age from 0.14 to 21 (median
9)years. 58% received transplants from an unrelated donor. All had
fully ablative transplants, 74% TBI based.
Results: Patients with platelet counts\100,000 at D100 had
a significantly increased risk of mortality (OR 2.21,p \0.0001).
Mean platelet count of those alive versus dead at any time after
100 days was 181,000 vs 101,000 (p\0.001) and mean platelet
count of those alive vs dead at 1 year post-HSCT was
177,000 vs 100,000 (p5.0002). TRM was strikingly increased
for patients in the low platelet group (OR16, p\0.0001). Those
dying from transplant-related causes had a mean platelet value of
65,000 at D100 compared to a mean value of 175,000 for those
who did not (p\0.001) The mean platelet count at D 100 was
not significantly different in patients who relapsed vs those who
did not.
Conclusion: Our results indicate that D100 platelet count has sig-
nificant prognostic value for subsequent mortality even though the
causes of thrombocytopenia in this setting are diverse. The increased
risk is primarily due to an increase in TRM in those with counts
\100,000. After D100 patients often have fewer physician visits
and care shared with non-HSCT providers. D100 platelet count is
a simple, inexpensive and reliable marker that can be used to identify
patients at risk for an adverse transplant outcome thus prompting
further evaluation and/or closer followup.249
EFFICACY OF MEROPENEM ANTIBACTERIAL PROPHYLAXIS FOLLOWING
MYELOABLATIVE PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT
(HSCT)
Bathurst, J.E.2, Williams, C.S.2, Hild, E.2, Quinones, R.R.1,2,
Keating, A.K.1,2, Foreman, N.K.1,2, Gore, L.1,2, Macy, M.1,2,
Flanagan, T.1,2, Peltz, A.1,2, Giller, R.H.1,2 1 University of Colorado
School of Medicine, Denver, CO; 2 The Children’s Hospital, Denver, CO
Poster Session I S251Neutropenia-associated bacteremia has been reported to occur in
20-60% of patients following myeloablative HSCT. Mortality up to
40% may occur with gram negative organisms. To address these
concerns, in 1998 our program revised supportive care guidelines
to include bacterial prophylaxis with meropenem for patients under-
going myeloablative HSCT. Meropenem was started when the
WBC fell below 1000/mcl and continued until the ANC
was$ 500/mcl. This report analyzes outcomes for patients treated
with this strategy.
Between 9/1/1998 and 9/1/2008, 370 transplants were performed.
Of these, 134 who underwent outpatient autologous HSCT received
different infection prophylaxis and were excluded from this analysis.
An additional 24 patients were excluded for other reasons (active bac-
terial infection prior to leukopenia5 15; never received
meropenem5 9). Thus, 212 transplants in 201 patients were evalu-
able for this retrospective analysis (auto5 67 HSCT/65 patients;
allo5 145 HSCT/136 patients). Evaluable patients had a median
of 19 days of ANC\500/mcl (range, 3 – 79 days) between the start
of myeloablation and subsequent myeloid engraftment. The study
group experienced 4409 total days of neutropenic risk for bacteremia.
The outlined strategy was successful in preventing a first bacter-
emic episode in 88% of evaluable transplants (94%, auto; 86%,
allo). Conversely, prophylaxis failed to prevent an initial neutropenic
bacteremia in 12% of transplants (n5 25) overall (6%, auto; 14%,
allo). Meropenem was started at a median of Day -2 (range, Day
-16 to Day +9) and continued for a median of 21 days (range, 1 –
81 days). Initial positive blood cultures occurred at a median of
Day +6 post-HSCT after a median of 10 days of meropenem. Pro-
phylaxis failures were primarily with organisms innately resistant
to meropenem (Coag Negative Staphylococci5 16; Enterococcus5 2;
Stenotrophomonas5 3; other5 4). No instances of meropenem-in-
duced resistant organisms were identified in failures of primary pro-
phylaxis. Initial bacteremias contributed to the deaths of 3 patients,
all post allogeneic HSCT. Thus, neutropenic bacteremias were the
cause of death in 1.4% of all transplants (3/212); none in autologous
HSCT (0/67), 2% in allogeneic HSCT (3/145).
In summary, these results suggest that prophylactic use ofmerope-
nem may be an effective strategy for reducing the risk of bacteremia
and septic death in children, adolescents and young adults undergo-
ing myeloablative autologous or allogeneic HSCT.250
PERFORMANCE CHARACTERISTICS OF GALACTOMANNAN ENZYME IM-
MUNOASSAY IN PEDIATRIC ALLOGENEIC HSCT RECIPIENTS
Lewis, J.A.1, Ragucci, D.P.2, Nista, E.J.1, Hudspeth, M.P.1 1 Medical
University of South Carolina, Charleston, SC; 2 Medical University of
South Carolina, Charleston, SC
Invasive fungal infections (IFI) are a major cause of morbidity and
mortality in allogeneic hematopoietic stem cell transplant (HSCT)
recipients. Galactomannan enzyme immunoassay (EIA) surveillance
testing offers the potential for earlier diagnosis and initiation of ther-
apy. Themajority of data regarding galactomannan EIA testing after
HSCT is reported in adult patients. Approval was obtained from the
Institutional Review Board at our institution for a retrospective chart
review of allogeneic HSCT patients from July 1, 2007 July 30, 2009.
Galactomannan EIA testing was obtained 314 times among the 27
patients for an average of 11.6 tests per patient. IFI was defined as ei-
ther proven or probable disease based on the EuropeanOrganization
for Research and Treatment of Cancer/Mycosis StudyGroup guide-
lines. Among the 27 patients, there were no cases of proven disease, 1
case of probable disease, and 8 cases of possible disease. There were 5
positive isolated tests without evidence of disease in 4 different pa-
tients. The galactomannan EIA had a sensitivity of 1.00, specificity
of 0.5, positive predictive value (PPV) of 0.07, and negative predic-
tive value (NPV) of 1. Of the 8 patients with possible IFI, 4 had
chronic GVHD. The galactomannan EIA values among the possible
IFI cases ranged from 0.59-7.69. The one probable IFI case also had
chronic GVHD and galactomannan EIA values ranged from 0.5-
1.12. Among the 4 patients with positive tests without evidence of
disease, the galactomannan EIA values ranged from 0.56- 8.57.
None of these patients had identified risk factors for false-positivetests such as administration of beta-lactam antibiotics or gastrointes-
tinal GVHD. Among our patients, the incidence of IFI was 3.7%,
well under the typically reported incidence of 7-10% in allogeneic
HSCT recipients. A decreased incidence and consequently de-
creased prevalence of IFI in our patients likely explains the decreased
PPV but preserved NPV of galactomannan EIA screening in our pe-
diatric allogeneic HSCT patients. HSCT centers should be aware of
the impact of their local incidence of IFI on the performance charac-
teristics of galactomannan EIA.
Table 1. Diagnostic Validity of Galactomannan EIA testing
Positive IFI Negative IFIPositive Galactomannan EIA 1 13
Negative Galactomannan EIA 0 13Sensitivity5 1/15 1.0 Specificity5 13/265 0.5 Positive Predictive Val-
ue5 1/145 0.07 Negative Predictive Value5 13/135 1.0251
EVALUATION OF THE CLINICAL OUTCOMES OF PEDIATRIC PATIENTS
WITH PERIPHERAL EOSINOPHILIA FOLLOWING HEMATOPOIETIC STEM
CELL TRANSPLANTATION
O’Hear, C.1, Eckstein, O.1, Lehmann, L.2, Duncan, C.2 1 Children’s Hos-
pital, Boston, MA; 2 Dana Farber Cancer Institute, Boston, MA
Eosinophilia has been proposed to have prognostic significance
for survival and for the development of graft-versus-host disease
(GVHD) in adult patients following hematopoietic stem cell trans-
plantation (HSCT). However, the prognostic significance of post-
transplant eosinophilia in regards to GVHD and overall survival
has not been well-studied in the pediatric population.We performed
a retrospective analysis of the clinical impact of eosinophilia in 84 pe-
diatric patients following allogeneicHSCTperformed for malignant
and non-malignant diseases. The clinical outcomes of patients with
eosinophilia were compared to patients transplanted during the
same time period that did not have eosinophilia. Eosinophilia was
defined as either an absolute number of greater than 0.5  10^9/L
or an eosinophil percentage greater than 4 in the peripheral blood
on at least two consecutive measurements. Seventy-one patients de-
veloped eosinophilia at a median 155 days from transplant. Forty-
two percent of patients had absolute eosinophilia and eighty-three
percent of patients had an elevated eosinophil percentage. The over-
all survival of all patients was sixty-nine percent. Thirty-six percent
of patients developed chronic GVHD and thirty percent developed
acute GVHD. Eosinophilia was not significantly associated with in-
creased mortality (odds ratio 2.7, 95% confidence interval 0.8-8.5);
acute GVHD (OR 2.6, CI 0.5-12.5), or chronic GVHD (OR 2.1,
CI 0.4-10.2). In this pediatric population, post-HSCT eosinophilia
does not have prognostic significance for mortality or the presence
or development of GVHD. Larger pediatric studies are needed to
further evaluate the impact of eosinophilia in children.252
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH
FANCONI ANEMIA: WHAT ARE THE NUTRITIONAL CONSENQUENCES?
Campos, D.J., Koerich, A., Biagini, G.L., Bonfim, C.M.S., Zanis Neto, J.,
Boguszewski, C.L., Borba, V.Z.C. Federal University of Parana, Curitiba,
PR, Brazil
Introduction: Fanconi Anemia (FA) is a rare disease characterized
by bone marrow failure, congenital abnormalities and a predisposi-
tion to cancer. Patients (pts) with FA usually have low birth weight,
short stature and fatigue. Hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for pts that develop hematological
abnormalities but it increases energy expenditure due to complica-
tions related to this procedure and decreases oral ingestion by the
presence of gastrointestinal symptoms.
Objective: Evaluate the changes in nutritional status, in food intake,
in bone mineral density (BMD) and in vitamin D serum levels in
